Neuroﬁbromatosis:AReviewofNF1,NF2,andSchwannomatosisJesseLeeKresak1MeggenWalsh11DepartmentofPathology,Immunology,andLaboratoryMedicine,UniversityofFlorida,Gainesville,Florida,UnitedStatesJPediatrGenet2016;5:98–104.AddressforcorrespondenceJesseLeeKresak,MD,DepartmentofPathology,UniversityofFlorida,1600SWArcherRoad,POBox100275,Gainesville,FL32610,UnitedStates(e-mail:jkresak@uﬂ.edu).NeuroﬁbromatosisNeuroﬁbromatosisisaheterogeneousgroupofhereditarycancersyndromesthatleadtotumorsofthecentralandperipheralnervoussystems.Byfarthemostcommonformisneuroﬁbromatosistype1(NF1,96%),followedbyneuroﬁbro-matosistype2(NF2,3%),andalesserknownform,schwanno-matosis.Neuroﬁbromatosishasnogenderorracialpredilection.NeuroﬁbromatosisType1IntroductionNF1,alsoknownasvonRecklinghausendiseaseorperipheralneuroﬁbromatosis,isanautosomaldominanttumorpredispo-sitionsyndromemostreadilycharacterizedbythedevelopmentofmultipleneuroﬁbromasoftheperipheralnerves.Theinci-denceofNF1isapproximately1inevery2,500to3,000births.1Lifeexpectancyisshortenedtoanaverageof54years,oftenonaccountofmalignancy.2MalignanciesassociatedwithNF1includemalignantperipheralnervesheathtumors,gliomas,leukemia,pheochromocytomas,gastrointestinal(GI)stromaltumors,andothers.NF1iscausedbyamutationintheneuro-ﬁbromintumorsuppressorgenelocatedonchromosome17.IthasahighrateofpenetranceandthemutationrateoftheNFgeneishighwith80%beingofpaternalorigin.3Theearliestknowndepictionofpresumedneuroﬁbromatosisdatesbacktothe13thcenturywithsketchesbyaCistercianmonk.4In1862,Virchowmadereferencetothehereditarycomponentwhenhedescribedamaninwhichthe“bodywasquitecoveredwithlumpsfrompinhead-sizedtopigeonegg-sized”andhenotedthatthe“peculiaritieshaveexistedinaninheritedmanneralreadyoverthreegenerations.”However,itwasVirchowstudent,FriedrichvonRecklinghausen,in1882thatgavethemostthoroughclinicalandhistologicalaccountofthediseaseandwhocoinedtheterm“neuroﬁbroma.”DiagnosticCriteriaThesymptomsofNF1canvarysigniﬁcantlyamongaffectedpatientsandthusatimelyandspeciﬁcdiagnosiscanbedifﬁculttoascertain.Thoughtheclinicaldiagnosismaybesuspectedveryearlyinchildhoodorinfancy,thecardinalfeaturesmaynotbeentirelypresentuntilanolderage.Approximately30%ofNF1patientswillmeetoneofthebelowcriterionbytheageof1year,97%ofpatientswillmeettwocriteriabytheageof8yearsand,inaretrospectivereviewofNF1patients,allpatientsmetthecriteriabytheageof20years.1In1987,theNationalInstitutesofHealth(NIH)developedaconsensusfordiagnosisduetoclinicalvariation.Theclinicaldiagnosiscanbeestablishedifthecriterialistedin►Table1aremetwithoutcausebyanalternatediagnosis.5Keywords►neuroﬁbromatosis►NF1►vonRecklinghausendisease►NF2►schwannomatosisAbstractTheneuroﬁbromatosesareaheterogeneousgroupofhereditarycancersyndromesthatleadtotumorsofthecentralandperipheralnervoussystems,aswellasotherorgansystems.Byfarthemostcommonformisneuroﬁbromatosis1(96%),followedbyneuroﬁbromatosis2(3%),andamorerecentlyrecognized,lesserknownform,schwannomatosis.Thediagnosticcriteria,pathogenesis,molecularconsiderations,andclinicalmanifestationsarediscussedinthisreviewarticle.receivedJuly10,2015acceptedafterrevisionAugust10,2015publishedonlineMarch9,2016IssueThemeHereditaryCancerSyndromesinChildren;GuestEditors:NicoleD.Riddle,MD,andRaulS.Gonzalez,MDCopyright©2016byGeorgThiemeVerlagKG,Stuttgart·NewYorkDOIhttp://dx.doi.org/10.1055/s-0036-1579766.ISSN2146-4596.ReviewArticle98This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.PathogenesisandGeneticConsiderationsThecausativegeneforNF1,wasidentiﬁedin1990anditwasfoundtobeoneofthelargestgenesinthehumangenomeencompassing280kbpofDNA.6TheNF1geneislocatedonchromosome17q11.2,whichencodesforaproteinknownasneuroﬁbromin.7NeuroﬁbrominbelongstotheGTPase-acti-vatingfamilyoftumorsuppressorproteinsthatregulatethefunctionoftheRAS/MAPKsignalingandmechanistictargetofrapamycin(mTOR)pathways.Approximately50%ofmuta-tionsaredenovo,occurringinpatientswithnofamilyhistory.Forfamilieswithaninheritedmutation,thereiscompletepenetrance;however,clinicalmanifestationsamongfamilymemberscanvarygreatly.Thevariabilityinphenotypicexpressionislikelyaresultofepigeneticmodiﬁcation.8Studiesaddressingthegenotype–phenotypecorrelationhavefoundthatdeletionoftheentiregene,knownas17q11.2microdeletion,isassociatedwithamoresevereformofthedisease,whilemosaicismcanleadtoamildorevensegmentalpresentation.6,7Nearly1,500differentmutationsoftheNF1genehavebeenidentiﬁedandthesemutationshavebeenfoundthroughouttheentirelengthofthelargegenelocus.6Non-sense,frameshift,andpointmutationshaveallbeenidenti-ﬁedwiththemajorityofthemutationsleadingtoatruncatedformoftheprotein.Genetictestingisoftenreservedforfamilymembersofapatientwhosepathologicalmutationhasbeenidentiﬁed,andthustheexactmutationcanbescreenedforintheirrelatives.Otherwise,giventheremarkablyhighdegreeofmutationsusceptibilityandthelackof“hotspots”onthegene,NF1doesnotlenditselftomutationalanalysisasapracticaldiagnostictool.6ThediagnosisofNF1ismostoftenmadeontheclinicalgroundsdiscussedabove.ClinicalManifestationsNeuroﬁbromasNeuroﬁbromas,thenamesakeofthedisease,arethemostcommontumorofNF1,occurringinapproximately60%ofthepatients.Histologically,neuroﬁbromasofNF1areindistin-guishablefromsporadictumors,albeittheformerareoftenlarger.Neuroﬁbromasmaybecutaneousorinternal,involv-ingdeepsofttissues.Thecutaneousformsmaybepeduncu-lated,nodular,orplaque-likedevelopinginlatechildhoodandincreasinginnumbersintoadulthood.2Theinternalordeepneuroﬁbromascanoccurthroughoutthebodyincludingperiorbital,retroperitoneal,GItract,andmediastinalloca-tions.9PathognomonicofNF-1,plexiformneuroﬁbromasareinternalneuroﬁbromasthat,ratherthangrowingintraneur-allywithinasinglenerve,growtoinvolvemultiplefasciclesorbranchesofanerveorplexus.Thisgrowthpatternlendsitselftothecharacteristic“bagofworms”descriptiongivenonpalpationorsurgicalexaminationofthesetumors.Plexiformneuroﬁbromasoftendevelopinchildhoodandgrowrapidly,exertingmasseffectonadjacentstructures.Unlikethecuta-neousform,plexiformneuroﬁbromashaveanincreasedriskoftransformationintomalignantperipheralnervesheathtumors(MPNST).MPNSTsarerareaggressivespindle-cellsarcomas,accountingforonlyapproximately5%ofallsofttissuesarcomas.About50%ofMPNSTsoccurinthesettingofNF1asthesepatientshavean8to13%riskofdevelopingoneintheirlifetime.3Suddenchangeorgrowthofaplexiformneuroﬁbromaonimagingsurveillance,aswellasincreaseduptakeonﬂuorodeoxyglucose-positronemissiontomogra-phy(PETscan),shouldraisesuspicionformalignanttransfor-mation.Treatmentforneuroﬁbromasincludessurgicalresectionandlasertherapy,whilethegoalofplexiformneuroﬁbromasurgeryisoftenfordebulking.Recentclinicaltrialsinvolvingtyrosinekinaseinhibitorimatinibhaveshownadecreaseintumorvolumebygreaterthan20%inasubsetofpatients.10Furtherstudiesaddressingthistherapy,aswellasmTORinhibitors,areunderway.10MPNSTsareasigniﬁcantcauseofmortalityinNF1patientsanddespiteradicalexcisionwithwidesurgicalmargins,followedbychemoradiation,5-yearsurvivalratesarepoorduetofrequentlungandbonemetastasesaswellaslocalrecurrence.2PigmentaryAbnormalitiesCafé-au-laitspotsarebenigntan-brownpigmentedmaculesthatcanoccuranywhereonthebody,andareoftenthepresentingsignofNF1.Bytheageof1year,99%ofthepatientswiththediagnosisofNF1willhavesixormorecafé-au-laitmaculesgreaterthan5mm(prepubertalcriteriaasperNIH).1,9ThoughacommonfeatureofNF1,café-au-laitspotsareanonspeciﬁcﬁndingastheycanbeseseeninapproximately10%ofthegeneralpopulationaswellasinothergeneticsyndromes—SilverRusselldwarﬁsm,MENIIb,Legiussyndrome,andMcCuneAlbrightsyndrome.ThenumericcutoffusedinthediagnosticcriteriaisbasedonastudybyCroweetalin1956inwhich78%ofthe203NF1patientsanalyzedhadatleastsixcafé-au-laitspotsgreaterthan15mm.11Thisquantityisgreaterthanthosereportedforthegeneralpopulation.Inaretrospectivereviewofinfantswithbirthmarks,Mihmetalshowedthat1.8%ofAfricanAmericaninfantswillhavethreeormorecafé-au-laitspots,whilenonsyndromicCaucasianinfantsrarelyhavetwoormore.12Histologically,theselesionsshowhyperpigmenta-tionofthebasalepidermiswithmacromelanosomespresent.9AlthoughthereisnopotentialformalignantTable1Clinicaldiagnosticcriteriaforneuroﬁbromatosistype1DiagnosticcriteriaofNF1Twoormoreofthefollowing:(cid:129)Atleastsixcafé-au-laitmacules(>5mmdiameterinprepubertalindividualsand>15mminpostpubertalindividuals)(cid:129)Frecklinginaxillaryoringuinalregions(cid:129)Opticglioma(cid:129)AtleasttwoLischnodules(irishamartomas)(cid:129)Atleasttwoneuroﬁbromasofanytype,oroneplexiformneuroﬁbroma(cid:129)Adistinctiveosseouslesion(sphenoiddysplasiaortibialpseudarthrosis)(cid:129)AﬁrstdegreerelativewithNF1JournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh99This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.transformation,cosmetictreatmentissometimessought.Casereportsshowthatsomepatientsmayhaveagoodresponsewithdermatologiclasertherapyfordepigmenta-tion;however,itmaytakeseveraltreatmentsforaresponseandasubsetofpatientswillhaverepigmentationofthelesionwithin6months.13FrecklingintheaxillaandgroinareanotherdeﬁningsymptomofNF1.Onlyapproximately40%ofpatientswillbenotedtohavefrecklingininfancyand90%ofNF1patientswillhavefrecklingbytheageof7years.1MelanocyticnodulescanalsooccurintheirisesofNF1patients.Thesesmall,oftenmultiple,hamartomatouslesions,knownasLischnodules,arefoundin93%ofadultswithNF1.Theyareasymptomatic.14GliomasPatientswithNF1areatanincreasedriskofdevelopinglow-andhigh-gradegliomas.ThemostcommonlyencounteredgliomainthesettingofNF1isalow-gradegliomaoftheopticnerve.Theseopticnervegliomasoccurinabout15%ofNF1patientsandusuallypresentbytheageof7years.2Generally,thesetumorsarepilocyticastrocytomas,WorldHealthOrganizationgradeI,andarehistologicallyequivalenttopilocyticastrocytomasofthegeneralpopulationwithabiphasicgrowthpattern,hair-likeprocesses,andRosenthalﬁbers.Giventheindolentnatureofthesetumors,managementusuallyconsistsofimagingsurveil-lance.Whenvisualacuitydeclines,chemotherapymaybeemployed.2ThelocationofthesetumorsdoesnotallowforsurgicalinterventionandradiationtherapyisavoidedinNF1patientsduetoincreasedriskofdevelopingradiation-inducedmalignancies.15BrainstemgliomasarethesecondmostfrequentgliomaofNF1andagain,thesetumorsareusuallypilocyticastrocytomas.Forthesamereasonsasopticgliomas,chemo-therapyistheonlytreatmentavailablewithagoalofsymptom-aticreliefandprolongedsurvival.Finally,NF1patientshaveaﬁvefoldriskofdevelopingmalignantgliomas,particularlyglio-blastomas,overthegeneralpopulationwithanaveragesurvivalofabout1year.MusculoskeletalManifestationsChildrenwithNF1haveasigniﬁcantlyincreasedriskfordevelopingrhabdomyosarcomaswithanapproximately20-foldincreaseoverthegeneralpopulation.2Theserhab-domyosarcomasmayarisefromanysite;however,alargereviewfoundapredominanceofbladderandprostatesitesoforigin.16Thetreatmentprotocolsfollowedfornonsyn-dromicrhabdomyosarcomasmayalsobeappliedtoNF1patients.VariableskeletalabnormalitiesarefrequentlynotedinNF1patients,includingosteopenia,scoliosis,andsphenoidwingorcongenitaltibiadysplasia.Inaddition,manypatientswithNF1willbeofshortstature;thoughtheirbodyproportionsremainnormal.17ThemechanisticassociationofNF1andskeletaldeformitiesislargelyunknown;however,NF1patientshavebeenreportedtohavelow-bonemineraldensitiesandlowconcentrationsofvitaminD.2StudieshaveindicatedathreefoldincreasefractureriskinNF1-affectedchildrenincreasingtoaﬁvefoldincreasedriskinadults.17,18Repeatfracturesinthesepatientsmayleadtopseudoarthrosis.GastrointestinalManifestationsTheGItractcanbeinvolvedbyneuroﬁbromasandmalignantperipheralnervesheathtumorssimilartoothersitesofthebody;however,alsotherearevariousotherGImalignanciesassociatedwithneuroﬁbromatosis.Asforneuroﬁbromas,theGItractcanbeinvolvedbyfocalneuroﬁbromasordiffuselybyaneuroﬁbromatousproliferationexpandingthelaminaprop-ria.Inbothinstances,ganglioncellsmaybeintermixedwithoutclinicalsigniﬁcance.GIstromaltumors(GIST)arenotuncommonoccurrencesinNF1patientsandhavebeenreportedinupto25%ofpatients.19IncontrasttoGISTsinthegeneralpopulation,NF1-associatedGISTsrarelyharbormutationsinKITorPDGFRA.Inamajorityofcases,theGISTissmall,asymptomatic,andfollowsabenigncourse.Histologically,theGISTsaresimilartononsyndromictumorscomposedofspindlecellandskeinoidﬁbers.EndocrinetumorsoftheGItractarealsoseeninNF1patientsandthesehaveapredilectionfortheperiampullaryregion.Themostcommonendocrinetumorreportedisasomatostatinoma;however,gastrinoma,insulinoma,carcinoids,andparagan-gliomashavealsobeendescribedinthissetting.19OtherMalignanciesPatientswithNF1alsohaveasigniﬁcantpredispositiontomalignanciesoutsideofthenervoussystem.ChildrenwithNF1haveasevenfoldincreasedriskofhematopoieticmalignancies,especiallymyeloidleukemia,comparedwiththeirage-matchedcounterparts.Thetreatmentandprognosisaresimilarforthesyndromicandgeneralpop-ulations.NF1patientsarealsoatanincreasedriskforthedevelopmentofbreastcancer,particularlyinwomenundertheageof50years.Again,thetreatmentisthesameforboththegroupsofpatients.Finally,althougharareoccur-rence,pheochromocytomasoftheadrenalglandareseenmorefrequentlyinNF1patientsthaninthegeneralpopu-lationwithareportedincidenceupto5%comparedwithlessthan1%.2Thepresentationforpheochromocytomasofteninvolvesﬂushing,palpitations,andhypertensionandsurgeryisoftencurative.Neuroﬁbromatosis2IntroductionNF2,alsoknownbilateralacousticneuroﬁbromatosisorcentralneuroﬁbromatosis,isahereditarytumorsyndromecharacterizedpredominantlybythedevelopmentofschwan-nomas,alongwithmeningiomas,ependymomas,andocularabnormalities.Despitethename,neuroﬁbromasarerela-tivelyinfrequent.NF2isinheritedinanautosomaldominantpatternwithanestimatedincidenceof1in25,000,preva-lenceof1in60,000,andapenetranceofapproximately0.95.20Patientsusuallypresentaroundage20andprognosticconsiderationsincludeageatdiagnosis,meningiomastatus,andaccesstospecialtymedicalcenters.21ThediseaseiscausedbyamutationintheNF2geneonchromosome22,whichencodesforaprotein,merlin.Overhalfofthecasesarecausedbydenovogenemutationsinpatientswithnofamilyhistoryofthedisease.JournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh100This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.DiagnosticCriteriaBilateralschwannomasofthesuperiorvestibularbranchoftheeighthcranialnerve(vestibularschwannomaoracousticneuroma)arepathognomonicforNF2.However,since41%ofpatientseventuallyproventohaveNF2donothavebilateralvestibularschwannomasattheinitialtimeofpresentation,therehavebeenseveraldiagnosticstandardscreatedforNF2.TheseincludethewidelyrecognizedManchestercriteriaaswellasadditionalNIHcriteriashownin►Table2.BaseretalrecentlyproposedascoringsystemtoreplacetheManchestercriteriawithreportedlyincreasedsensitivitywhilemaintain-ing100%speciﬁcity.21,22PathogenesisandGeneticConsiderationsNF2wasproventobegeneticallydistinctentityfromNF1whenlinkagestudiesdiscoveredanovelprovenin1993.23,24Thesestudiesfoundthediseasetobecausedbyabnormalitiesofagenelocatedontheq12bandofchromosome22.ThisNF2genecodesfortheproteinmerlin(alsoknownasschwanno-min),whichisatumorsuppressorproteinimpactingPI3kinase/Akt,Raf/MEK/ERK,andmTORsignalingpathways.Merlinisnamedforitsrelationshiptothemoesin(membraneorganizingextensionspikeprotein)—erzin(cytovillin)—radixinfamilyofcytoskeleton-associatedproteins,23whichsuggeststhatitmaybeinﬂuentialincommunicationbetweensurfacesignalingandthecytoskeletonmatrix.Mutationsinmerlincanbefoundinapproximately93%ofpatientswithclinicalevidenceofNF2andapositivefamilyhistory.25Amoleculardiagnosisismoreelusivetoﬁndinpatientswithdenovomutations,59%,duetosomaticmosaicism,26whichispresentin30to60%ofdenovocases.Inmosaiccases,themutationisharboredwithinthetumoritselfandonlyasubsetofcirculatinglymphocytespickeduponaroutinebloodtest.Recentstudieshavefoundthat,whilepenetrancelevelswillbedifferentfortheoffspringofamosaicpatientthanforafullypenetrantfamilialpatient,thereisstillariskoftrans-missionofthediseaseinthesettingofanondetectablemutationintheblood.Ithasbeenestimatedthattheriskoftransmissiondropsfromtheautosomaldominant50%toaround8to12%dependingoninitialclinicalpresentation.ThephenotypeofNF2canhavevaryingdegreesofseverity.Withinanaffectedfamily,thenaturalhistoryandphenotypicexpressionofNF2isusuallysimilarbetweenitsmembers.However,interfamilyvariationscanbestriking.Thedifferencescanbeattributedtodifferingabnormalitieswith-intheNF2gene.Forinstance,themostsevereclinicalmanifestationshavebeenassociatedwithframeshiftornon-sensemutations,whichalsohappentobethemostcommonmutationtypes,inwhichthemutationcausestruncatedproteinexpression.Ananalysisof268NF2patientsbySelvanathanetalfoundthatpatientswhoharboredmuta-tionsleadingtotruncatedproteinexpressionwerediagnosedatayoungerageandhadahigherprevalenceofmeningiomas,spinaltumors,andcutaneoustumors.27Theyoungerageofdiagnosiswasfoundattributabletoearliersymptomaticpresentations,especiallytinnitus,wasting,andweakness.Incontrast,mutationsresultinginlargedeletionsormissensemutationsleadtoamilderdiseasepresentation.Smithetalreportedthat,inadditiontomutationtype,thepositionofthemutationwithinthegenealsohadphenotypicimplications.Mutationstowardthe5′endofthegeneareassociatedwithahigherprevalenceofintracranialmeningiomas,whereasmutationsinexons14and15conferalowerrisk.28Itwasalsonotedinthisstudythat,whilethereisafemalepredomi-nanceofdevelopingmeningiomasinthegeneralpopulation,thereisnogenderpredilectionformeningiomaswithinNF2patients.ClinicalManifestationsNF2predisposespatientstothedevelopmentofnervoussystemtumors,includingpredominantlyschwannomasfollowedbymeningiomas,andependymomas.Inaddition,patientsarealsoaffectedbyocularmanifestations.ThehallmarkandpathognomonicﬁndingofNF2isbilateralvestibularschwannomas,whichcanbefoundin90to95%ofNF2patients.VestibularSchwannomasVestibularschwannomas,alsoknownasacousticneuromas,presentwithtinnitus,gradualhearingloss,andbalancedysfunction.Usuallypresentbytheageof30years,thesetumorsarisefromthesuperiordivisionoftheeighthcranialnervewithintheinternalauditorymeatus.Histologically,vestibularschwannomasinNF2aresimilartosporadicschwannomasbydisplayingcharacteristicalternatingAntoniAandBregions,Verocaybodies,andhyalinizedvessels.Incontrasttosporadicschwannomas,vestibularschwannomasofNF2areoftenmultifocal,asevidencedbyradiographicstudies29andappearmultilobulatedorbotryoidatthetimeofsurgery.Infact,arecentstudyhasfoundthateachofthesetumorsor“lobules”harborsadmixedcellpopulationswithvarioussomaticNF2mutations,supportingpolyclonalityTable2Clinicaldiagnosticcriteriaforneuroﬁbromatosistype2MaincriteriaAdditionalcriteriaBilateralvestibularschwannomasorUnilateralvestibularschwannomaplusanytwoofthefollowing:meningioma,glioma,schwannoma,orjuvenileposteriorlenticularopacitiesorFirst-degreerelativewithneuroﬁbromatosistype2plus1.Unilateralvestibularschwannomasor2.Anytwoofthefollowing:Meningioma,glioma,schwannoma,orjuvenileposteriorlenticularopacitiesAtleasttwomeningiomasplus1.Unilateralvestibularschwannomaor2.Anytwoof:glioma,neuroﬁbroma,schwannoma,andcataractJournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh101This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.withmultipledistincttumorclones.30Thisﬁndingmayexplainthedisparitiesobservedintreatmentoutcomeswhencomparingwithsporadiccases.Treatmentisusuallyreservedforcaseswithsigniﬁcantimpactonqualityoflife,particularlyhearingpreservation,orforinstanceswhenthetumorgrowsmediallyandcausesbrainstemcompression.Forsporadictumors,surgeryandradiosurgeryhavebeenthemainstaysoftherapeuticintervention;however,bothoptionsaremorecomplexinthesettingofNF2.Surgeryhasasimilarhearingpreservationrateofapproximately50%betweenbothsporadicandNF2tumors,however,recurrenceratesforNF2vestibularschwannomasareabout44%comparedwith1.3%fortheirsporadiccounterparts.31Thisdiscrepancyisattrib-utabletothemultifocalgrowthpatternaswellastheten-dencyofthetumortoinvolvethefacialnerve.Thus,thereisalsoincreasedriskoffacialnerveinjuryandconsequentialeyelidandlacrimalglanddysfunction.Ifsurgicalresectionyieldsanintactcochlearnerve,cochlearimplantationcanbeutilizedforfurtherimprovementinhearingoutcomes.32StereotacticradiationhasasigniﬁcantlypoorerhearingpreservationrateforNF2tumorscomparedwithsporadic,andthismaybeinpartduetohistologicaltendencyofNF2schwannomastoinvadenerveﬁbers,ratherthandisplacethemassporadictumorsdo,whichleadstoinevitablenervedamagewhentargetingwithradiationorsurgery.33Also,thereappearstobeagreaterriskofmalignanttransformationfollowingradiationinvestibularschwannomasofNF2patients.31Finally,chemotherapywithbevacizumab,avascularendothelialgrowthfactorinhibitor,hasrecentlybeenutilizedwithpromisingsuccessshowingaclinicalresponseofhearingimprovementin57%ofcasesandtumorshrinkagein53%;however,toxicitiesincludinghypertensionandproteinuriaarenotuncommon.34,35PeripheralSchwannomasSchwannomasofothercranialandperipheralnerves,especiallyparaspinalandcutaneousnerves,areencounteredinupto70%ofpatientswithNF2.36Symptomsattributabletoperipheralschwannomasaremostoftenpain,sensoryloss,andweakness.Aswiththevestibularschwannomas,thehistologyofperipheralschwannomasofNF2andsporadicschwannomasaresimilarwiththeexceptionofthetendencyofNF2schwannomastoinﬁltratetheassociatednerve.Also,immunohistochemicalstudyforINI1(SMARCB1)displaysamosaicpatternofexpressioninsyndromictumorsasopposedtointactpositivityinsporadiccases.36TheﬁndingofSMARCB1alterationsintheseschwannomasraisesthepos-sibilityofadiagnosisofschwannomatosisratherthanNF2(see“Schwannomatosis”discussionbelow),howeverinmostcases,theotherclinicalormolecularcriteriaofNF2arepresent.MinuteSchwanncellneoplasms,calledtumorlets,arenotuncommoninNF2patientsandareoftenfoundstuddedalongtheparaspinalnerveroots.Thesetumorletsarebelievedtobeschwannomaprecursorsinthesepatients.37SimilartoplexiformneuroﬁbromasofNF1,plexiformschwannomasinvolvingmorethanonenervefasciclearemorecommonlyseeninNF2patientsandtheﬁndingofaplexiformschwannomaconfersa10to50%chancethatthepatientinfacthasNF2.38,39Plexiformschwannomasaremostoftencutaneousorsubcutaneouswithapredilectionfortheheadandneckregion.IncontrasttotheneuroﬁbromasofNF1,schwannomasofNF2rarelyundergomalignanttrans-formation.Excisionisthetreatmentofchoiceforperipheralschwannomasandsurgicaloutcomesarereportedlyvaried.SomeauthorsreportaworsepostsurgicaloutcomeforNF2-associatedschwannomasincomparisontosporadicschwan-nomas,asmaybeexpectedduetotheirinﬁltrativenatureandplexiformsubtypes,whileothersreportgreatimprovementinneurologicdeﬁcitsamongboththepatientgroups.40MeningiomasMeningiomasoccurinabout50%ofNF2patientsandareassociatedwithsigniﬁcantmorbidityandmortalityinthispopulation.Mostareintracranialmeningiomasandfre-quentlymultiple,thoughspinalmeningiomasalsooccur.Symptomsfromanintracranialmeningioma,suchashead-acheorseizure,arethepresentingsymptominupto30%ofpatientseventuallyfoundtohaveNF2.20MeningiomasoccuratayoungerageinNF2patientsthaninthegeneralpopula-tion,andinfact,approximately20%ofpediatricpatientsdiagnosedwithameningiomawillbefoundtohaveNF2.41EpendymomasGlialneoplasmsarerelativelyuncommoninNF2withtheexceptionofintramedullaryspinalependymomas.SpinalependymomasinNF2haveapredilectionforthecervicalandcervicomeduallryjunction,withabout85%occurringinthisregion,42andcommonlypresentasmultipletumorswitha“stringofpearl”appearanceinthecord.Histologically,thetumorsareoftenlow-gradeclassicortanycyticependymo-mas.EpendymomasofNF2patientsareoftenasymptomaticandareonlyidentiﬁedbyroutineimagingsurveillanceandthusthemainstayoftherapyismonitoring.OcularManifestationsOphthalmiccomplicationsarefoundinamajorityofpatientswithNF2.Themostcommonocularmanifestationisacataractcausedbyposteriorsubcapsularlenticularopacitieswhichispresentinupto80%ofNF2patients.43Additionalocularﬁndingsincludeepiretinalmembranes,retinalhamar-tomas,opticnervegliomas,andmeningiomas,andintraocu-larschwannomas.SchwannomatosisIntroductionSchwannomatosis,asthenameimplies,isasyndromecharacterizedbythedevelopmentofmultipleperipheralnerveschwannomas,withoutconcomitantinvolvementofthevestibularnerve.Sincetheschwannomaisthepredomi-nanttumorinbothNF2andschwannomatosis,therecanbeconsiderableoverlapinthephenotypesofthesesyndromesandassuchschwannomatosisisoftencategorizedasthethirdformofneuroﬁbromatosis.However,geneticallytheyaretwodistinctentities.TheprevalenceofschwannomatosisisJournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh102This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.difﬁculttoassessgiventheclinicalsimilaritiestoNF2andlackofareliablegenetictestinallcases,thoughitisspeculatedtobeaboutascommonasNF2.36PathogenesisandGeneticConsiderationsSchwannomatosisiscausedbyamutationintheSMARCB1gene,alsoknownastheINI1,BAF47,orhSNF5gene,locatedonchromosome22q11.2,centromerictotheNF2gene.Themajor-ityofthecasesofschwannomatosisarecausedbydenovomutations,thoughfamilialcasesexistwithanautosomaldomi-nantinheritancepattern.44Eveninthefamilialforms,agermlineSMARCB1mutationisonlyidentiﬁedin40to50%ofcases,26suggestinginvolvementofothergeneticlociyettobeidentiﬁed.GenetictestingiscomplicatedbythepresenceofsomaticNF2mutationsfoundinmanytumorsofpatientswithschwanno-matosis.Therefore,molecularstudiesperformedonseveraltumorsmayberequiredbeforeadeﬁnitivediagnosiscanbemade.SMARCB1mutationsarealsoresponsiblefortherhabdoidtumorsofrhabdoidpredispositionsyndrome,however,rarelydothesetwosyndromesoverlapclinically.Thedifferencesintumorigenesis,outcome,andpresentationforthesetwosyndromeswithasharedmutationisnotcompletelyunder-stood,thoughmaybearesultoftruncatedversusnontruncatedproteinsorepigeneticfactors.26DiagnosticCriteriaDiagnosticcriteriaforschwannomatosisarenotyetasstandard-izedastheyarefortheothertwoneuroﬁbromatoses.Currently,thediagnosiscanbemadeonamolecularorclinicalbasis.Clinically,apatientcanbediagnosedwithschwannomatosiswiththefollowingstipulations:(1)atleasttwonondermalbiopsy-provenschwannomaswithnoradiographicevidenceofbilateralvestibularschwannomasonhigh-qualitymagneticresonanceimagingor(2)onebiopsy-provennondermalschwannomaorintracranialmeningiomaandaﬁrst-degreerelativewithschwannomatosis.Ithasalsobeenproposedthatapatientwithtwoormorenondermaltumorsthataresuspi-ciousforschwannomas,butwithouthistologicalconﬁrmation,beconsidered“possible”foradiagnosisofschwannomatosis.26Finally,asbilateralvestibularschwannomasofNF2mayoccurinthethirddecadeoflife,anagecutoffofatleast30yearsmaybeemployedtoensureanaccuratediagnosisofschwannomato-sis.26Molecularly,thediagnosiscanbemadeifapatient(1)hasabiopsy-provenschwannomaormeningiomaandagermlineSMARCB1mutation,or(2)hasatleasttwobiopsy-provenschwannomasormeningiomaswithasharedSMARB1mutationanddifferingNF2mutations,asoutlinedin►Table3.ClinicalManifestationsSchwannomasThoughschwannomasarecommontobothschwannomatosisandNF2,thereareclinicaldifferences.Theageatpresentationforschwannomatosispeaksinadulthood,usuallybetweentheagesof30and60years,44andoftenwithchronicdebilitatingpain.Incontrast,NF2canbereliablydiagnosedinearlychildhoodandmorecommonlypresentswithneurologicaldeﬁcits.Histologically,sporadicschwannomasandsyndromicschwannomasareindistinguishable;how-ever,similartoNF2,theschwannomasofschwannomatosistendtohaveanintraneuralgrowthpattern,peritumoraledema,myxoidchange,andamosaicINI1stainingpatternbyimmunohistochemistry.26,45Managementisclinicalobservationforasymptomaticpatients.Incasesofspinalcordcompressionorbothersomesymptoms,surgeryisper-formedtoimprovequalityoflife.References1DeBellaK,SzudekJ,FriedmanJM.Useofthenationalinstitutesofhealthcriteriafordiagnosisofneuroﬁbromatosis1inchildren.Pediatrics2000;105(3Pt1):608–6142HirbeAC,GutmannDH.Neuroﬁbromatosistype1:amultidisci-plinaryapproachtocare.LancetNeurol2014;13(8):834–8433WeissS,etal.EnzingerandWeiss’sSoftTissueTumors.Philadel-phia,PA.ElsevierSaunders;20144BrosiusS.AhistoryofvonRecklinghausen’sNF1.JHistNeurosci2010;19(4):333–3485WilliamsVC,LucasJ,BabcockMA,GutmannDH,KorfB,MariaBL.Neuroﬁbromatosistype1revisited.Pediatrics2009;123(1):124–1336AbramowiczA,GosM.Neuroﬁbromininneuroﬁbromatosistype1-mutationsinNF1geneasacauseofdisease.DevPeriodMed2014;18(3):297–3067BoydKP,KorfBR,TheosA.Neuroﬁbromatosistype1.JAmAcadDermatol2009;61(1):1–14,quiz15–168FernerRE.Neuroﬁbromatosis1.EurJHumGenet2007;15(2):131–1389RosaiJ,etal.RosaiandAckerman’sSurgicalPathology.10thed.Philadelphia,PA:ElsevierSaunders;201110RobertsonKA,NalepaG,YangFC,etal.Imatinibmesylateforplexiformneuroﬁbromasinpatientswithneuroﬁbromatosistype1:aphase2trial.LancetOncol2012;13(12):1218–1224Table3DiagnosticcriteriaforschwannomatosisClinicalcriteriaMolecularcriteria(cid:129)Atleasttwonondermalbiopsy-provenschwannomasplusnoradiographicevidenceofbilateralvestibularschwannomasonhigh-qualityMRIor(cid:129)Biopsy-provenschwannomaormeningiomaplusagermlineSMARCB1mutationor(cid:129)Onebiopsy-provennondermalschwannomaorintracranialmeningiomaplusaﬁrst-degreerelativewithschwannomatosis(cid:129)Atleasttwobiopsy-provenschwannomasormeningiomasharboringasharedSMARCB1mutationanddifferingNF2mutationsAbbreviations:NF2,neuroﬁbromatosistype2;MRI,magneticresonanceimaging.JournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh103This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.11CroweFW,etal.AClinical,PathologicalandGeneticStudyofMultipleNeuroﬁbromatosis.Springﬁeld,IL:CharlesCThomas;195612AlperJ,HolmesLB,MihmMCJr.Birthmarkswithseriousmedicalsigniﬁcance:nevocullularnevi,sebaceousnevi,andmultiplecaféaulaitspots.JPediatr1979;95(5Pt1):696–70013ShimbashiT,KamideR,HashimotoT.Long-termfollow-upintreatmentofsolarlentigoandcafé-au-laitmaculeswithQ-switchedrubylaser.AestheticPlastSurg1997;21(6):445–44814YanoffM,SassaniJ.OcularPathology.Philadelphia,PA:ElsevierSaunders;200915SharifS,FernerR,BirchJM,etal.Secondprimarytumorsinneuroﬁbromatosis1patientstreatedforopticglioma:substantialrisksafterradiotherapy.JClinOncol2006;24(16):2570–257516SungL,AndersonJR,ArndtC,RaneyRB,MeyerWH,PappoAS.NeuroﬁbromatosisinchildrenwithRhabdomyosarcoma:areportfromtheIntergroupRhabdomyosarcomastudyIV.JPediatr2004;144(5):666–66817TuckerT,SchnabelC,HartmannM,etal.Bonehealthandfracturerateinindividualswithneuroﬁbromatosis1(NF1).JMedGenet2009;46(4):259–26518HeerväE,KoffertA,JokinenE,etal.Acontrolledregister-basedstudyof460neuroﬁbromatosis1patients:increasedfractureriskinchildrenandadultsover41yearsofage.JBoneMinerRes2012;27(11):2333–233719AgaimyA,VassosN,CronerRS.Gastrointestinalmanifestationsofneuroﬁbromatosistype1(Recklinghausen’sdisease):clinico-pathologicalspectrumwithpathogeneticconsiderations.IntJClinExpPathol2012;5(9):852–86220EvansDG,HusonSM,DonnaiD,etal.Aclinicalstudyoftype2neuroﬁbromatosis.QJMed1992;84(304):603–61821BaserME,FriedmanJM,AeschlimanD,etal.Predictorsoftheriskofmortalityinneuroﬁbromatosis2.AmJHumGenet2002;71(4):715–72322BaserME,FriedmanJM,WallaceAJ,RamsdenRT,JoeH,EvansDG.Evaluationofclinicaldiagnosticcriteriaforneuroﬁbromatosis2.Neurology2002;59(11):1759–176523TrofatterJA,MacCollinMM,RutterJL,etal.Anovelmoesin-,ezrin-,radixin-likegeneisacandidatefortheneuroﬁbromatosis2tumorsuppressor.Cell1993;72(5):791–80024RouleauGA,MerelP,LutchmanM,etal.Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneuro-ﬁbromatosistype2.Nature1993;363(6429):515–52125EvansDG,RamsdenRT,ShentonA,etal.Mosaicisminneuroﬁbro-matosistype2:anupdateofriskbasedonuni/bilateralityofvestibularschwannomaatpresentationandsensitivemutationanalysisincludingmultipleligation-dependentprobeampliﬁca-tion.JMedGenet2007;44(7):424–42826LoveS,PerryA,IronsideJ,BudkaH.Greenﬁeld’sNeuropathology.9thed.BocaRaton,FL:CRCPress;201527SelvanathanSK,ShentonA,FernerR,etal.Furthergenotype—phenotypecorrelationsinneuroﬁbromatosis2.ClinGenet2010;77(2):163–17028SmithMJ,HiggsJE,BowersNL,etal.Cranialmeningiomasin411neuroﬁbromatosistype2(NF2)patientswithprovengenemuta-tions:clearpositionaleffectofmutations,butabsenceoffemaleseverityeffectonageatonset.JMedGenet2011;48(4):261–26529StivarosSM,Stemmer-RachamimovAO,AlstonR,etal.Multiplesynchronoussitesoforiginofvestibularschwannomasinneuro-ﬁbromatosisType2.JMedGenet2015;52(8):557–56230DewanR,PemovA,KimHJ,etal.Evidenceofpolyclonalityinneuroﬁbromatosistype2-associatedmultilobulatedvestibularschwannomas.Neuro-oncol2015;17(4):566–57331ManiakasA,SalibaI.Neuroﬁbromatosistype2vestibularschwan-nomatreatment:areviewoftheliterature,trends,andoutcomes.OtolNeurotol2014;35(5):889–89432NeffBA,WietRM,LasakJM,etal.Cochlearimplantationintheneuroﬁbromatosistype2patient:long-termfollow-up.Laryngo-scope2007;117(6):1069–107233HamadaY,IwakiT,FukuiM,TateishiJ.AcomparativestudyofembeddednervetissueinsixNF2-associatedschwannomasand17nonassociatedNF2schwannomas.SurgNeurol1997;48(4):395–40034PlotkinSR,MerkerVL,HalpinC,etal.Bevacizumabforprogressivevestibularschwannomainneuroﬁbromatosistype2:aretrospec-tivereviewof31patients.OtolNeurotol2012;33(6):1046–105235SlusarzKM,MerkerVL,MuzikanskyA,FrancisSA,PlotkinSR.Long-termtoxicityofbevacizumabtherapyinneuroﬁbromatosis2patients.CancerChemotherPharmacol2014;73(6):1197–120436HiltonDA,HanemannCO.Schwannomasandtheirpathogenesis.BrainPathol2014;24(3):205–22037Stemmer-RachamimovAO,InoY,LimZY,etal.LossoftheNF2geneandmerlinoccurbythetumorletstageofschwannomadevelopmentinneuroﬁbromatosis2.JNeuropatholExpNeurol1998;57(12):1164–116738BergJC,ScheithauerBW,SpinnerRJ,AllenCM,KoutlasIG.Plexi-formschwannoma:aclinicopathologicoverviewwithemphasisontheheadandneckregion.HumPathol2008;39(5):633–64039Hébert-BlouinMN,AmramiKK,ScheithauerBW,SpinnerRJ.Multinodular/plexiform(multifascicular)schwannomasofmajorperipheralnerves:anunderrecognizedpartofthespectrumofschwannomas.JNeurosurg2010;112(2):372–38240BendonCL,FurnissD,GieleHP.Comparisonofoutcomesofperiph-eralnerveschwannomaexcisioninneuroﬁbromatosistype2patientsandnon-neuroﬁbromatosistype2patients:Acasecontrolstudy.JPlastReconstrAesthetSurg2015;68(9):1199–120341EvansDG,BirchJM,RamsdenRT.Paediatricpresentationoftype2neuroﬁbromatosis.ArchDisChild1999;81(6):496–49942PlotkinSR,O’DonnellCC,CurryWT,BoveCM,MacCollinM,NunesFP.SpinalependymomasinneuroﬁbromatosisType2:aretro-spectiveanalysisof55patients.JNeurosurgSpine2011;14(4):543–54743McLaughlinME,PepinSM,MaccollinM,ChoopongP,LessellS.Ocularpathologicﬁndingsofneuroﬁbromatosistype2.ArchOphthalmol2007;125(3):389–39444KoontzNA,WiensAL,AgarwalA,HingtgenCM,EmersonRE,MosierKM.Schwannomatosis:theoverlookedneuroﬁbromato-sis?AJRAmJRoentgenol2013;200(6):W646-5345MacCollinM,ChioccaEA,EvansDG,etal.Diagnosticcriteriaforschwannomatosis.Neurology2005;64(11):1838–1845JournalofPediatricGeneticsVol.5No.2/2016Neurofibromatosis:AReviewofNF1,NF2,andSchwannomatosisKresak,Walsh104This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.